Preservation And Generation Of Beta Cells In Type 1 Diabetes With Novel Mimetic Peptides
Funder
National Health and Medical Research Council
Funding Amount
$1,096,055.00
Summary
Type 1 diabetes (T1D) is an autoimmune disease that destroys insulin producing beta cells in the pancreas. It can cause heart and kidney disease, and nerve damage. T1D is treated with insulin injections that can cause life-threatening low blood sugar levels. We have developed a new treatment that may stop beta cell loss, generate new beta cells and remove the need for insulin injections in T1D patients. A positive outcome will identify a completely new T1D treatment option.
Protein Preloads To Improve Postprandial Glycaemia In Type 2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$624,458.00
Summary
Taking a high protein drink can substantially lower the blood glucose rise after a subsequent meal in people with type 2 diabetes. We will examine whether regular use of protein drinks before meals can be effective for improving long-term blood glucose control. Such an approach could represent an exciting new nutritional strategy for managing this increasingly common disorder.
Exploring The Role Of Glycogen Structure In Type 2 Diabetes.
Funder
National Health and Medical Research Council
Funding Amount
$367,126.00
Summary
The incidence of type 2 diabetes, a disease hallmarked by poor blood glucose control, is rapidly increasing in Australia. This project will investigate the role of liver-glycogen, our blood glucose buffer, in the pathology type 2 diabetes, with particular focus on the glycogen’s structure. By determining the importance of glycogen structure on its properties and how this affects diabetic’s blood glucose levels will potentially result in new drug target for the treatment of type 2 diabetes.
Upper Gastrointestinal Motility And Glycaemic Control In Diabetes Mellitus
Funder
National Health and Medical Research Council
Funding Amount
$543,301.00
Summary
The application of novel techniques to evaluate gastrointestinal motor function has established that the rate at which the stomach empties is abnormally slow in ~50% of people who have insulin-dependent (type 1) or non-insulin dependent (type 2) diabetes. Delayed stomach emptying, which was thought to be an infrequent complication of diabetes, may contribute to a number of problems including symptoms such as nausea and bloating, and poor control of blood glucose concentrations. The blood glucose ....The application of novel techniques to evaluate gastrointestinal motor function has established that the rate at which the stomach empties is abnormally slow in ~50% of people who have insulin-dependent (type 1) or non-insulin dependent (type 2) diabetes. Delayed stomach emptying, which was thought to be an infrequent complication of diabetes, may contribute to a number of problems including symptoms such as nausea and bloating, and poor control of blood glucose concentrations. The blood glucose level itself also has a reversible effect on both stomach contractions and symptoms; when the blood glucose is abnormally high, the rate at which the stomach empties is slower, and symptoms, such as fullness, are greater. The rate of stomach emptying and the absorption of sugar from the intestine have a major influence on the rise in the blood glucose level after a meal. This is important because in people with diabetes it is desirable to maintain blood glucose levels as close as possible to normal to minimise the risk of complications such as eye and nerve damage. Specific modifications in diet and recently developed drugs which have actions similar to that of the hormone, glucagon-like peptide-1, may improve blood glucose control in type 2 diabetes by slowing the rate of gastric emptying. People with cystic fibrosis frequently develop diabetes which is often difficult to manage; this may result from abnormally rapid gastric emptying and impaired release of hormones. If so, pancreatic enzyme replacement, in the form of tablets, should prove effective. Our group has conducted research in this area for about 24 years and have performed the most comprehensive studies to date resulting in international recognition. The studies proposed in the current application represent a logical development from our previous work and have important implications for the management of diabetes.Read moreRead less
This clinical trial will test whether a combination of two safe therapies, abatacept and nasal insulin, can stop the immune attack that causes type 1 diabetes. Sixty-two children and young adults with recently-diagnosed type 1 diabetes will receive either abatacept and nasal insulin or abatacept and nasal placebo for one year to determine if combined immune therapy preserves pancreas function and decreases the need for insulin therapy.
Determinants Of Glycemic Control In Australian Children With Type 1 Diabetes- A National Population Based Study.
Funder
National Health and Medical Research Council
Funding Amount
$90,524.00
Summary
The aim of the study is to examine the influence of practices and therapies used in Australian youth with Type 1 Diabetes and the clinical and demographic predictors of blood glucose control. Optimized blood glucose control reduces the risk of progression to kidney disease, vision impairment and cardiovascular disease. This study will provide insight into the influences on blood glucose control, including those that are modifiable. This will provide an evidence base to inform clinical practice.
Culturally Appropriate Diabetes Care In Mainstream General Practice For Urban Aboriginal And Torres Strait Islander People
Funder
National Health and Medical Research Council
Funding Amount
$381,291.00
Summary
Main study objectives are to determine the enablers and barriers for urban Indigenous people to access mainstream primary care services, in particular diabetes chronic care services. This knowledge of critical access and acceptability factors will guide the development of a culturally approirate diabetes care intervention for Indigenous patients. This adpated intervention, to be delivered in mainstream general practices, will be pilot-tested for cultural appropriateness in Indigenous patients.